Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg®
10 February 2013 | By Novo Nordisk
“We are convinced that Tresiba® and Ryzodeg® offer significant benefits...”
List view / Grid view
News
Pergamum AB announces a strategic collaboration with Cadila Pharmaceuticals Ltd
8 February 2013 | By Cision
Pergamum AB and Cadila Pharmaceuticals Ltd announced a strategic collaboration...
Amgen announces call for nominations for 2013 Breakaway from Cancer® Champions
8 February 2013 | By Amgen
Four inspirational individuals making a positive impact for those affected by Cancer...
New Phase 3 data reinforce long-lasting protection from bleeding for patients with Hemophilia A and B
8 February 2013 | By Biogen Idec
Biogen Idec and Swedish Orphan Biovitrum released data...
Gilead Sciences completes acquisition of YM BioSciences
8 February 2013 | By
Gilead Sciences, Inc. announced that it has completed its acquisition of YM BioSciences Inc...
BioCity Scotland announced as UK hub for major European drug discovery project
7 February 2013 | By University of Dundee
"We are absolutely delighted that the European Lead Factory will be co-located in Scotland..."
€196 million Pan-European drug discovery platform launched
7 February 2013 | By Innovative Medicines Initiative (IMI)
Large pharmaceutical companies join forces with small and medium-sized enterprises (SMEs) and academia in an IMI-supported public private partnership (PPP) to enhance early drug discovery and so address the ever-increasing need for innovative therapeutics to tackle unmet medical needs...
Nottingham in €196 million European drug discovery drive
7 February 2013 | By The University of Nottingham
Pioneering chemists from The University of Nottingham are taking part in the biggest-ever European research programme...
Tecan’s multimode readers offer staying power for biomolecular research
7 February 2013 | By kdm communications limited
Scientists at the University of Toronto, Canada, have chosen generations of Tecan microplate readers to monitor...
Amgen Outlines Long-Term Strategy
7 February 2013 | By Amgen
Amgen outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City...
European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma
7 February 2013 | By GlaxoSmithKline
GSK announced submission of a Marketing Authorisation Application...
Biogen Idec to acquire full rights and control of TYSABRI® from Elan for upfront cash and contingent payments
6 February 2013 | By Biogen Idec
Biogen Idec has agreed to purchase Elan’s interest in TYSABRI...
Avacta launches application-focused Optim® 2
5 February 2013 | By kdm communications limited
Avacta Analytical has unveiled the Optim® 2 micro-volume protein analysis and characterisation instrument...
European Commission approves HUMIRA’s label update
AbbVie has announced the European Commission (EC) has approved an update to the label for HUMIRA® (adalimumab) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). The update adds data demonstrating the long-term clinical benefit of HUMIRA, making it the first and only biologic medication available with…
ZALTRAP® (aflibercept) approved in the EU
5 February 2013 | By Sanofi
First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimen...
